AtriCure Price Target Raised to $25.00 at Canaccord Genuity (ATRC)
Investment analysts at Canaccord Genuity upped their price target on shares of AtriCure (NASDAQ:ATRC) from $19.00 to $25.00 in a note issued to investors on Friday, AnalystRatingsNetwork reports. Canaccord Genuity’s price target would indicate a potential upside of 31.51% from the stock’s previous close.
Shares of AtriCure (NASDAQ:ATRC) traded up 16.41% on Friday, hitting $22.13. The stock had a trading volume of 778,625 shares. AtriCure has a 1-year low of $7.39 and a 1-year high of $19.20. The stock has a 50-day moving average of $16.84 and a 200-day moving average of $12.36. The company’s market cap is $465.2 million.
AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.15) by $0.02. The company had revenue of $20.10 million for the quarter, compared to the consensus estimate of $18.30 million. During the same quarter in the prior year, the company posted ($0.16) earnings per share. The company’s quarterly revenue was up 24.8% on a year-over-year basis. On average, analysts predict that AtriCure will post $-0.46 earnings per share for the current fiscal year.
AtriCure, Inc, is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.